By David Guet, Thomas Le Meur - 05 Feb 2021
For years now, digital pathology has seen the emergence of a plethora of heterogeneous different image types designed for clinical research use or routine diagnostics. Among them one can find tissue microarrays, or TMAs, introduced in the 1990s. TMA images differ from standard histopathological samples; instead of having a whole tissue section on a single slide, we find a large number of tissue cores organized on a grid, from different patients and, possibly from different tissue types. On one TMA slide, we can find several hundred samples.
02 Nov 2020
Background. During this collaboration between CILcare and KeenEye Technologies, a full pipeline has been designed to automatically classify and quantify the number of hair cells in 3D cochlea images.
01 Oct 2020
Abstract Background. In recent years, deep learning has been increasingly applied to a vast array of ophthalmological diseases. Inherited retinal diseases (IRD) are rare genetic conditions with a distinctive phenotype on fundus autofluorescence imaging (FAF).
01 Sep 2020
For the past decade, the medical and computer science communities have been working together to develop efficient computer-aided decision tools, using technological advances in both fields, to improve research and diagnosis.
22 Jul 2020
AI Platform for enterprise-wide tissue analysis and secure clinical research. If you are interested in improving your workflow, simplifying image management and analysis, and learning how enterprise-wide deployment delivers secure and traceable results – subscribe to our webinar!
01 Jul 2020
Many pharmaceutical companies develop their AI capabilities to improve operational efficiencies, scientific research, and the clinical trial process. As for medical image analysis, the complexity and heavy investment of time and effort lead them to turn to specialized partners who possess this expertise. Keen Eye holds a prominent position in this field with significant knowledge inAI, deep learning, and evaluation of large sets of histopathological, diagnostic and molecular images.
26 Jun 2020
In this webinar you will gain a deeper understanding of what deep learning is, how it works in reproducing pathologist’s expertise in the biomarker analysis of histopathological samples and why this is technology is the key to unlocking the future for biomarker discovery in drug development.
01 Jun 2020
Keen Eye continues to grow its business in 2020, taking on clients in the pharmaceutical research sector as well as biotechnology partners. This creates new demands on the technology associated with managing projects of an increased scale and reach.
01 May 2020
At the forefront of AI research in medicine are diagnostics and drug development. Deep learning technology allows better decision making, improved efficiency in clinical trials, and a clearer path to drug development.